Evidence map›Paper›PMID 30611703›Full record

ArticleAlcohol (Fayetteville, N.Y.)2019

Effect of nanoformulated copper/zinc superoxide dismutase on chronic ethanol-induced alterations in liver and adipose tissue.

Gopalakrishnan Natarajan, Curtis Perriotte-Olson, Carol A Casey, Terrence M Donohue, Geoffrey A Talmon, Edward N Harris, Alexander V Kabanov, Viswanathan Saraswathi

Open access · greenAbstract read
In one paragraph

Article in Alcohol (Fayetteville, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Pathogenesis of Alcohol-Associated Liver Disease.Journal of clinical and experimental hepatology
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Gopalakrishnan NatarajanDepartment of Internal Medicine, Divisions of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, United States.
Curtis Perriotte-OlsonDepartment of Internal Medicine, Divisions of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, United States.
Carol A CaseyDepartment of Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, NE, United States; VA Nebraska-Western Iowa Health Care System, Omaha, NE, United States.
Terrence M DonohueDepartment of Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, NE, United States; VA Nebraska-Western Iowa Health Care System, Omaha, NE, United States.
Geoffrey A TalmonDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States.
Edward N HarrisDepartment of Biochemistry, University of Nebraska at Lincoln, Lincoln, NE, United States.
Alexander V KabanovDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Viswanathan SaraswathiDepartment of Internal Medicine, Divisions of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, United States; VA Nebraska-Western Iowa Health Care System, Omaha, NE, United States. Electronic address: s.viswanathan@unmc.edu.
Nebraska Medical Center · USUniversity of Nebraska Medical Center · USUniversity of Nebraska–Lincoln · USUniversity of North Carolina at Chapel Hill · US

Funding

Liver-Mediated Clearance of Low Molecular Weight HeparinsR01HL130864 · NHLBI · UNIVERSITY OF NEBRASKA LINCOLN · PI HARRIS, EDWARD N · 2016 to 2019
$1.6M
The Effectiveness of NanoSOD in Ameliorating Ethanol-induced Liver Injury in ObesityR21AA025445 · NIAAA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI VISWANATHAN, SARASWATHI · 2017 to 2018
$331k
NHLBI NIH HHS R01 HL130864NIAAA NIH HHS R21 AA025445
6 · The paper itself

Abstract

backgroundWe previously reported that nanoformulated copper/zinc superoxide dismutase (Nano) attenuates non-alcoholic fatty liver disease and adipose tissue (AT) inflammation in obese animals. Here, we sought to determine whether Nano treatment attenuates alcohol-associated liver disease (AALD) and AT inflammation in alcohol-fed mice.

methodsWe pre-treated E-47 cells (HepG2 cells that over-express CYP2E1) with native- or nano-superoxide dismutase (SOD) for 6 h, followed by treatment with ethanol and/or linoleic acid (LA), a free fatty acid. For in vivo studies, male C57BL/6 mice were fed the Lieber-DeCarli control or ethanol liquid diet for 4 weeks. The mice received Nano once every 2 days during the last 2 weeks of ethanol feeding.

resultsOur in vitro studies revealed that Nano pretreatment reduced LA + ethanol-induced oxidative stress in E-47 cells. Our in vivo experiments showed that ethanol-fed Nano-treated mice had 22% lower hepatic triglyceride levels than mice fed ethanol alone. Nano-treated ethanol-fed mice also had 2-fold lower levels of Cd68 and similarly reduced levels of Ccl2 and Mmp12 mRNAs, than in untreated ethanol-fed mice. We also noted that ethanol feeding caused a remarkable increase in hepatic and/or plasma MCP-1 and CCR2 protein, which was blunted in ethanol + Nano-treated animals. The hepatic content of SREBP-1c, a transcription factor that promotes lipogenesis, was higher in ethanol-fed mice than controls but was attenuated in ethanol + Nano-treated animals. Further, livers of ethanol + Nano-treated mice had significantly higher levels of phosphorylated adenosine monophosphate-activated protein kinase (AMPK) than both control and ethanol-fed mice. In AT, the levels of Il6 mRNA, a hepatoprotective cytokine, and that of Arg1, a marker of anti-inflammatory macrophages, were significantly increased in ethanol + Nano-treated mice compared with control mice.

conclusionOur data indicate that Nano treatment attenuates ethanol-induced steatohepatitis and that this effect is associated with an apparent activation of AMPK signaling. Our data also suggest that Nano induces Arg1 and Il6 expression in AT, suggesting anti-inflammatory effects in this tissue.

Indexed as

Adipose TissueAMP-Activated Protein Kinase KinasesAnimalsAntigens, CDAntigens, Differentiation, MyelomonocyticCD68 MoleculeChemokine CCL2Cytochrome P-450 CYP2E1Drug CompoundingEthanolFree Radical ScavengersGene ExpressionHep G2 CellsHumansInflammationLipid MetabolismAMP-Activated Protein Kinase KinasesAntigens, CDAntigens, Differentiation, MyelomonocyticCcl2 protein, mouseCcr2 protein, mouseCD68 MoleculeCD68 protein, mouseChemokine CCL2Cytochrome P-450 CYP2E1EthanolFree Radical Scavengersmatrix metallopeptidase 12, mouseMatrix Metalloproteinase 12Protein KinasesReceptors, CCR2Sterol Regulatory Element Binding Protein 1Superoxide DismutaseAMPKEthanolMCP1SOD1Steatohepatitis

Identifiers

PMID30611703
PMCPMC6610811
OpenAlexW2907908830

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.